Navigation Links
Bend Research Signs Technology Licensing Agreement with Merck
Date:11/14/2011

BEND, Ore., Nov. 14, 2011 /PRNewswire/ -- Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, announced today that it has entered into a licensing agreement with Merck, through a subsidiary.

Under the terms of the agreement, Bend Research will provide Merck access to its proprietary spray-dried dispersion (SDD) technology. Depending on Merck's additional needs, Bend may also provide Merck with access under the license agreement to additional drug-delivery platforms and intellectual property, including modified-release technologies and drug-discovery formulation tools.

Under the collaboration, the two companies hope to use their complementary fundamental scientific and engineering capabilities to solve complex formulation and process-development problems with an eye toward transferring these solutions to a cGMP environment.

"We are excited to extend our working relationship with Merck," said Rod Ray, Chief Executive Officer of Bend Research. "Building stronger collaborative relationships with leading companies like Merck is important to Bend Research's future. This relationship expands our opportunities to deliver best-in-class medicines and fits well with Merck's mission to help provide innovative products that save and improve people's lives."

About Bend Research Inc.

For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including solubilization technologies such as SDDs and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies.

Bend Research has more than 240 employees based in four state-of-the-art facilities in Bend, Ore., USA.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
3. Millar Instruments, Inc. and Telemetry Research Ltd Merge
4. Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016
5. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
6. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
7. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
8. Critical Alerts For Barrick Gold, Molycorp, Lockheed Martin, Teva Pharmaceutical, and Tenaris Released By Seven Summits Research
9. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
10. Caliper Launches New Platform for Drug Safety Prediction and Oncology Research
11. JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):